Mahesan Subramaniam: Scientists Develop Antibody to Block Epstein-Barr Virus Infection
Mahesan Subramaniam, Co-Founder of United Health Tourism, posted on LinkedIn:
“Scientists created an antibody that can eradicate an infection that affects 95% of the global population.
The Epstein-Barr virus (EBV) is one of the world’s most pervasive pathogens, infecting nearly 95% of humans and persisting for life.
While widely known for causing mononucleosis, EBV is also a primary driver of several cancers, including lymphomas, and has been linked to severe neurological and chronic conditions.
Scientists at Fred Hutch Cancer Center have now achieved a significant breakthrough by developing human monoclonal antibodies designed to block the virus’s entry into human immune cells.
By targeting specific proteins the virus uses to attach and invade, this new approach has successfully prevented infection in advanced laboratory models, offering a potential solution to a decades-old medical challenge.
This development is particularly critical for the more than 128,000 Americans who undergo organ or bone marrow transplants annually.
In these vulnerable patients, EBV can reactivate and trigger post-transplant lymphoproliferative disorder, a life-threatening form of cancer with few preventative options.
The researchers envision a future where high-risk individuals receive antibody infusions to neutralize the virus before it can cause harm.
Although human clinical trials are the next necessary step, this Discovery represents a major leap toward controlling a quietly dangerous virus that has eluded effective prevention since its discovery.”

Stay updated with Hemostasis Today.
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma
-
Aug 14, 2026, 11:21Osama Alabdi: Never Ignore a Weak Reaction in the Blood Bank
-
Aug 14, 2026, 11:14Yohan Santin: How Lysosomal Dysfunction Drives Cardiac Aging
-
Aug 14, 2026, 11:06Nicolas Schommer: When Neutrophils Turn Metabolic Stress Into Organ Injury
-
Aug 14, 2026, 10:49Pablo Corral: Can One Infusion Lower LDL for Years
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children